Search results for "fusions"

showing 10 items of 176 documents

Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized s…

2002

Abstract Purpose: To compare a regimen of vinorelbine and cisplatin (VC) to the combination of mitomycin, vindesine, and cisplatin (MVP) in patients with stage IIIB or stage IV non-small cell lung cancer (NSCLC). The main endpoits were analysis of objective response rates, toxicity, time to progression, and overall survival. Patients and methods: 247 eligible patients were randomized to receive (a) vinorelbine 25 mg/m 2 intravenous bolus on days 1and 8 plus cisplatin 100 mg/m 2 on day 1 every 4 weeks, or (b) mitomycin c 8 mg/m 2 i.v. on day 1, vindesine 3 mg/m 2 i.v. on days 1, 8, 15 and 22, plus cisplatin 100 mg/m 2 on day 1 every 4 weeks. In subsequent cycles vindesine was given every oth…

Pulmonary and Respiratory MedicineAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsVindesinemedicine.medical_treatmentMitomycinVinorelbineVinblastineGastroenterologyDisease-Free SurvivalInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesInfusions IntravenousAgedNeoplasm StagingCisplatinChemotherapyPerformance statusDose-Response Relationship Drugbusiness.industryMitomycin CVinorelbineMiddle Agedmedicine.diseaseSurgerySurvival RateRegimenTreatment OutcomeOncologyDisease ProgressionVindesineFemaleCisplatinbusinessProgressive diseasemedicine.drugLung cancer (Amsterdam, Netherlands)
researchProduct

The actual management of colorectal liver metastases

2020

Colorectal cancer is one of the most frequent cancers in the world and between 50% and 60% of patients will develop colorectal liver metastases (CRLM) during the disease. There have been great improvements in the management of CRLM during the last decades. The combination of modern chemotherapeutic and biological systemic treatments with aggressive surgical resection strategies is currently the base for the treatment of patients considered unresectable until few years ago. Furthermore, several new treatments for the local control of CRLM have been developed and are now part of the arsenal of multidisciplinary teams for the treatment of these complex patients. The aim of this review was to s…

ReoperationSurgical resectionmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerLeucovorinDisease030230 surgery03 medical and health sciencesHepatic Artery0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsHepatectomyHumansInfusions Intra-ArterialMedicineMicrowavesRadiofrequency Ablationbusiness.industryGeneral surgeryLiver NeoplasmsMargins of ExcisionPrognosismedicine.diseaseLiver TransplantationElectroporation030220 oncology & carcinogenesisCamptothecinSurgeryFluorouracilColorectal NeoplasmsbusinessMinerva Chirurgica
researchProduct

Expansión y crecimiento de las cooperativas de crédito durante el período 1993-2007 en la Comunidad Valenciana

2009

La Comunidad Valenciana es junto con Andalucía y el País Vasco, las Comunidades Autónomas donde más imbricadas se hallan las cooperativas de crédito; estas se han vinculado al sector agrario vía cajas rurales en las dos primeras, y al sector industrial, vía cajas populares, en la tercera. En este trabajo se analiza la evolución en los últimos quince años, período 1993-2007, del crédito cooperativo en la Comunidad Valenciana, materializado en el estudio de las cajas rurales con sede social en la misma. En él destacamos la experiencia de concentración de algunas entidades, así como la reciente creación de otras a partir de secciones de crédito de cooperativas agrarias. El estudio se efectúa c…

Rural Savings BanksConcentrationMergerCooperative Credit ; Rural Savings Banks ; Concentration ; Strategies ; MergerUNESCO::CIENCIAS ECONÓMICASConcentraciónLa ConcentrationUn crédit Coopératif ; les Boîtes rurales ; La Concentration ; Les Stratégies ; Les FusionsLes Stratégies:CIENCIAS ECONÓMICAS [UNESCO]FusionesCrédito Cooperativo ; Cajas rurales ; Concentración ; Estrategias ; FusionesCrédito CooperativoLes FusionsStrategiesUn crédit Coopératifles Boîtes ruralesCooperative CreditCajas ruralesEstrategias
researchProduct

Apport partiel d'actif : l'apport de titres de participation peut-il être soumis au régime juridique de la scission ?

2014

International audience; Note sous Cour d'appel de Paris, 4 février 2014, n° 12/16545, C. c/ SAS CA Comunication Multimedia

Régime fiscal des fusions[SHS.DROIT]Humanities and Social Sciences/Law[SHS.DROIT] Humanities and Social Sciences/LawFusion et scissionApport de titres sociauxSOCIETE EN GENERALRégime des scissions
researchProduct

Fusions

2020

First volume of the journal on the interdisciplinary concept of fusions

Settore INF/01 - InformaticaSettore L-FIL-LET/08 - Letteratura Latina Medievale e Umanisticafusions digital public
researchProduct

The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societi…

2021

The personalized medicine is in a rapidly evolving scenario. The identification of actionable mutations is revolutionizing the therapeutic landscape of tumors. The morphological and histological tumor features are enriched by the extensive genomic profiling, and the first tumor-agnostic drugs have been approved regardless of tumor histology, guided by predictive and druggable genetic alterations. This new paradigm of "mutational oncology", presents a great potential to change the oncologic therapeutic scenario, but also some critical aspects need to be underlined. A process governance is mandatory to ensure the genomic testing accuracy and homogeneity, the economic sustainability, and the r…

Societies ScientificGenomic profilingDruggabilityNTRK-FusionsMedical OncologyNeoplasmsMedicineHumansAgnostic biomarkersPrecision MedicineHistology-agnosticTumor histologybusiness.industryAgnostic biomarkers; Agnostic drugs; Histology-agnostic; Homologous recombination deficiency; Microsatellite instability; Mismatch repair deficiency; NTRK-Fusions; Precision oncology; Humans; Italy; Medical Oncology; Precision Medicine; Neoplasms; Societies ScientificScientificPrecision oncologyHematologyPrecision medicineData scienceAgnostic drugsOncologyEconomic sustainabilityItalyAgnostic biomarkerMicrosatellite instabilityPosition paperNeoplasmIdentification (biology)Personalized medicineAgnostic drugNTRK-FusionbusinessSocietiesHomologous recombination deficiencyMismatch repair deficiencyHuman
researchProduct

Stability of irinotecan-loaded drug eluting beads (DC BeadTM) used for transarterial chemoembolization

2009

Purpose. The aim of this study was to determine the loading efficiency, physicochemical stability, and release of irinotecan-loaded DC BeadsTM (bead size 100—300 μm, 300—500 μm) before and after mixing with nonionic contrast medium (Accupaque® 300, Imeron® 300, Ultravist ® 300) during a prolonged period of time (28 days) when stored at room temperature or refrigerated. Methods. DC Beads TM were loaded with 50 mg irinotecan (Campto®) per milliliter beads in a 2 h loading period. Drug loading efficiency and stability were determined by measuring the irinotecan concentration in the excess solution. A free-flowing in vitro elution method for a period of 2 h and phosphate buffered solution (PBS…

Time FactorsDrug CompoundingDrug StorageContrast MediaBeadIrinotecanchemistry.chemical_compoundDrug Delivery SystemsDrug StabilityIntra arterialInfusions Intra-ArterialMedicinePharmacology (medical)Chemoembolization TherapeuticParticle SizeSolubilityChromatography High Pressure LiquidChromatographyDrug eluting beadsbusiness.industryElutionTemperaturePhosphateAntineoplastic Agents PhytogenicMicrospheresIrinotecanSolubilityOncologychemistryvisual_artvisual_art.visual_art_mediumCamptothecinParticle sizebusinessmedicine.drugJournal of Oncology Pharmacy Practice
researchProduct

Cerebral toxicity of penicillins in relation to their hydrophobic character

1975

The neurotoxic effects of ticarcillin, methicillin, phenthicillin, oxacillin, cloxacillin and dicloxacillin were studied in the conscious rabbit. During and after intravenous administration of 1.2 and 2.4 g/kg, resp., over 50 min the blood concentrations of the drugs were determined and the neurotoxicity assessed by continuous recording of the electroencephalogram. The hydrophobia of the penicillins was characterized by determination of their partition coefficients between isobutanol and buffer solution pH 7.4. The penicillins showed quite different neurotoxic properties. A close correlation (r = 0.928) was found between the neurotoxic potency of the penicillins and their partition coeffici…

Time FactorsHydrophobiaPenicillinsPharmacologyDicloxacillinMethicillinStructure-Activity RelationshipCloxacillinpolycyclic compoundsmedicineAnimalsTicarcillinPotencyDicloxacillinInfusions ParenteralcvgOxacillinPharmacologyChromatographyChemistrycvg.computer_videogameNeurotoxicityBrainElectroencephalographyGeneral Medicinebiochemical phenomena metabolism and nutritionmedicine.diseasePartition coefficientPenicillinKineticsTicarcillinPenicillin VFemaleRabbitsCloxacillinmedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Long-term stability study of clofarabine injection concentrate and diluted clofarabine infusion solutions

2011

Purpose: The aim of this study was to investigate the physicochemical stability of clofarabine (CAFdA) injection concentrate and ready-to-use CAFdA infusion solutions over a prolonged period of 28 days. Methods: To determine the stability of CAFdA infusion solutions, the injection concentrate (Evoltra®, 1 mg/mL, Genzyme) was diluted either with 0.9% sodium chloride or 5% glucose infusion solution. The resulting concentrations of 0.2 mg/mL or 0.6 mg/mL, respectively, were chosen to represent the lower and upper limit of the ordinary concentration range. Test solutions were stored under refrigeration (2–8°C) or at room temperature either light protected or exposed to light. CAFdA concentrati…

Time FactorsStability studyDrug StorageSodiumchemistry.chemical_elementAntineoplastic AgentsInjection concentratechemistry.chemical_compoundGlucose infusionDrug StabilitymedicineClofarabinePharmacology (medical)Clofarabine InjectionInfusions IntravenousChromatography High Pressure LiquidChromatographyAdenine Nucleotidesbusiness.industryReproducibility of ResultsPolyethylenePharmaceutical SolutionsPolyvinyl chlorideOncologychemistryArabinonucleosidesbusinessClofarabinemedicine.drugJournal of Oncology Pharmacy Practice
researchProduct

Correction of the unfavourable effects of vasopressin by nitroglycerin infusion

1982

Nitroglycerin was administered with vasopressin to prevent adverse effects. Vasopressin 0.25U . 70 kg-1 min-1 was infused intravenously in four dogs for 40 minutes, when a venous infusion of nitroglycerin 1.2 micrograms . kg-1 . min-1 was added for 20 minutes. Nitroglycerin 1.2 micrograms . kg-1 . min-1 alone was infused intravenously in another four dogs for 40 minutes. The venous blood pressures (mesenteric and central) and arterial pressures (mesenteric and femoral), the electrocardiogram and arterio-venous difference were recorded. Nitroglycerin was shown to annul the unfavourable effects of vasopressin without altering its efficacy upon portal pressure.

Vasopressinmedicine.medical_specialtyTime FactorsCentral Venous PressureVasopressinsPortal venous pressureBlood PressureNitroglycerinDogsOxygen ConsumptionHeart RateAnesthesiologyAnimalsMedicineInfusions Parenteralcardiovascular diseasesAdverse effectNitroglycerinbusiness.industryGeneral MedicineVenous Blood PressuresAnesthesiology and Pain MedicineAnesthesiacardiovascular systembusinesscirculatory and respiratory physiologymedicine.drugCanadian Anaesthetists’ Society Journal
researchProduct